Descriptive Study of the Incidence of Malignancy in Patients with Severe Asthma Overall and Among Those Receiving Benralizumab and Other Therapies, a Post Authorization Safety StudyFirst published 14/11/2018 Last updated 27/06/2024 EU PAS number: EUPAS26310StudyOngoing
Optimum Patient Care (OPC)United Kingdom First published: 01/02/2024Last updated 01/02/2024 InstitutionNot-for-profit
Parexel InternationalSweden First published: 19/10/2010Last updated 26/04/2024 InstitutionNon-Pharmaceutical companyENCePP partner
Optimum Patient Care (OPC) NetworkUnited Kingdom (Northern Ireland) First published: 26/09/2015Last updated 08/08/2023 NetworkENCePP partner
Respiratory Effectiveness Group (REG)BelgiumDenmarkFranceGermanyGreeceHungaryItalyNetherlandsSpainSwedenUnited Kingdom First published: 07/07/2021Last updated 04/06/2024 NetworkENCePP partner